KR960703591A - 신경변성 질병에서 플로피르틴의 일차적 및 이차적 신경보호 효과(The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases) - Google Patents
신경변성 질병에서 플로피르틴의 일차적 및 이차적 신경보호 효과(The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases) Download PDFInfo
- Publication number
- KR960703591A KR960703591A KR1019960700753A KR19960700753A KR960703591A KR 960703591 A KR960703591 A KR 960703591A KR 1019960700753 A KR1019960700753 A KR 1019960700753A KR 19960700753 A KR19960700753 A KR 19960700753A KR 960703591 A KR960703591 A KR 960703591A
- Authority
- KR
- South Korea
- Prior art keywords
- flupyritin
- medicament
- manufacture
- active substance
- treatment
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract 5
- 230000004770 neurodegeneration Effects 0.000 title claims 2
- JUUFBMODXQKSTD-UHFFFAOYSA-N N-[2-amino-6-[(4-fluorophenyl)methylamino]-3-pyridinyl]carbamic acid ethyl ester Chemical compound N1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 JUUFBMODXQKSTD-UHFFFAOYSA-N 0.000 title 1
- 229960003667 flupirtine Drugs 0.000 title 1
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract 16
- 238000004519 manufacturing process Methods 0.000 claims abstract 16
- 201000006474 Brain Ischemia Diseases 0.000 claims abstract 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract 2
- 206010010904 Convulsion Diseases 0.000 claims abstract 2
- 231100001018 bone marrow damage Toxicity 0.000 claims abstract 2
- 210000004556 brain Anatomy 0.000 claims abstract 2
- 231100000874 brain damage Toxicity 0.000 claims abstract 2
- 206010008118 cerebral infarction Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims 16
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000472 traumatic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Confectionery (AREA)
- Medicinal Preparation (AREA)
Abstract
플루피르틴의 NMDA 길항효과는 뇌허혈증, 신경변성 장애, 외상성 뇌 및 골수 손상, 간질 발작 및 기타 질환의 치료를 위한 약제의 제조를 가능케 한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (16)
- 뇌 허혈증의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 신경변성 질병의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 간질 발작의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 파킨슨씨 질병의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 알츠하이머 질병의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 헌팅톤 무도병의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 다발성 경화증의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 근위축성측색경화증의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 감염-유발성 신경변성 장애의 퇴치를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 대사-독성 신경변성 장애의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 망막의 변성 및 허혈성 장애의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 외상-유도된 뇌 및 골수 손상의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 뇌 과흥분성 증후군의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 말초 신경계 변성증후군의 치료를 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 신경이완 진통을 위한 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.
- 파킨슨씨 질병의 치료를 위한 플루피르틴 및 L-도파 및 도파민으로부터의 배합 약제를 제조하기 위한 활성 물질 플루피르틴의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4327516A DE4327516A1 (de) | 1993-08-17 | 1993-08-17 | Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin |
DEP4327516.8 | 1993-08-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR960703591A true KR960703591A (ko) | 1996-08-31 |
KR100341952B1 KR100341952B1 (ko) | 2003-04-11 |
Family
ID=6495312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960700753A KR100341952B1 (ko) | 1993-08-17 | 1994-08-10 | 신경퇴행성질환에서플로피르틴의일차적및이차적신경보호효과 |
Country Status (27)
Country | Link |
---|---|
US (1) | US5721258A (ko) |
EP (1) | EP0716602B1 (ko) |
JP (1) | JPH09501664A (ko) |
KR (1) | KR100341952B1 (ko) |
CN (1) | CN1086291C (ko) |
AT (1) | ATE210442T1 (ko) |
AU (1) | AU694447B2 (ko) |
BG (1) | BG62430B1 (ko) |
BR (1) | BR9407293A (ko) |
CA (1) | CA2169718C (ko) |
CZ (1) | CZ289040B6 (ko) |
DE (2) | DE4327516A1 (ko) |
DK (1) | DK0716602T3 (ko) |
EE (1) | EE03204B1 (ko) |
ES (1) | ES2168309T3 (ko) |
HR (1) | HRP940464A2 (ko) |
HU (1) | HU227765B1 (ko) |
IL (1) | IL110681A (ko) |
NO (1) | NO309842B1 (ko) |
NZ (1) | NZ273292A (ko) |
PT (1) | PT716602E (ko) |
RU (1) | RU2166318C2 (ko) |
SK (1) | SK283330B6 (ko) |
UA (1) | UA43351C2 (ko) |
WO (1) | WO1995005175A1 (ko) |
YU (1) | YU49215B (ko) |
ZA (1) | ZA946176B (ko) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19539861A1 (de) * | 1995-10-26 | 1997-04-30 | Asta Medica Ag | Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen |
DE19541405A1 (de) * | 1995-11-07 | 1997-05-15 | Asta Medica Ag | Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen |
DE19625582A1 (de) * | 1996-06-27 | 1998-01-02 | Asta Medica Ag | Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen |
ES2235368T3 (es) * | 1997-10-27 | 2005-07-01 | Sumitomo Pharmaceuticals Company, Limited | Derivados de amida para tratar alteraciones neurodegenerativas de la retina. |
AU1359801A (en) * | 1999-11-05 | 2001-06-06 | Vela Pharmaceuticals Inc. | Methods and compositions for treating reward deficiency syndrome |
US6821995B1 (en) | 1999-12-01 | 2004-11-23 | Duke University | Method of treating batten disease |
AU1353901A (en) * | 1999-12-01 | 2001-06-12 | Duke University | Method of treating batten disease |
DE10327674A1 (de) | 2003-06-20 | 2005-01-05 | Awd.Pharma Gmbh & Co. Kg | Injizierbare Darreichungsform von Flupirtin |
DE10328260A1 (de) * | 2003-06-23 | 2005-01-27 | Schmidt, K.-G., Dr. med. | Flupirtine-Präparat |
CN1917876A (zh) * | 2003-12-16 | 2007-02-21 | Cns生物有限公司 | 方法和组合物 |
WO2006065204A1 (en) * | 2004-12-14 | 2006-06-22 | Astrazeneca Ab | Substituted aminopyridines and uses thereof |
EP1688141A1 (en) | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
US20060258708A1 (en) * | 2005-05-16 | 2006-11-16 | Andrulis Peter J Jr | Method for treating Parkinson's disease and other neurological diseases |
US20080279930A1 (en) * | 2007-05-07 | 2008-11-13 | Bernd Terhaag | Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof |
DE102011006425A1 (de) | 2010-03-31 | 2011-10-06 | Awd.Pharma Gmbh & Co. Kg | Pharmazeutische Zubereitung und deren Verwendung |
DE102010030053A1 (de) | 2010-06-14 | 2011-12-15 | Awd.Pharma Gmbh & Co.Kg | Injizierbare Darreichungsform von Flupirtin |
EP3027188A4 (en) * | 2013-07-31 | 2017-03-01 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and flupirtine |
WO2019014547A1 (en) * | 2017-07-14 | 2019-01-17 | Texas Tech University System | FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY |
DE102017007385A1 (de) | 2017-08-02 | 2019-02-07 | Christoph Hoock | Maleatfreie feste Arzneimittelformen |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481205A (en) * | 1980-09-13 | 1984-11-06 | Degussa Aktiengesellschaft | 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate |
DE3369315D1 (en) * | 1982-10-27 | 1987-02-26 | Degussa | Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity |
DE3337593A1 (de) * | 1982-10-27 | 1984-05-03 | Degussa Ag, 6000 Frankfurt | 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung |
NO860825L (no) * | 1985-03-23 | 1986-09-24 | Degussa | Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin. |
IN172468B (ko) * | 1990-07-14 | 1993-08-14 | Asta Medica Ag |
-
1993
- 1993-08-17 DE DE4327516A patent/DE4327516A1/de not_active Ceased
-
1994
- 1994-08-10 EP EP94926828A patent/EP0716602B1/en not_active Expired - Lifetime
- 1994-08-10 DK DK94926828T patent/DK0716602T3/da active
- 1994-08-10 HU HU9600355A patent/HU227765B1/hu unknown
- 1994-08-10 WO PCT/EP1994/002649 patent/WO1995005175A1/en active IP Right Grant
- 1994-08-10 ES ES94926828T patent/ES2168309T3/es not_active Expired - Lifetime
- 1994-08-10 SK SK214-96A patent/SK283330B6/sk not_active IP Right Cessation
- 1994-08-10 PT PT94926828T patent/PT716602E/pt unknown
- 1994-08-10 RU RU96105707/14A patent/RU2166318C2/ru active
- 1994-08-10 AU AU76528/94A patent/AU694447B2/en not_active Expired
- 1994-08-10 KR KR1019960700753A patent/KR100341952B1/ko active IP Right Grant
- 1994-08-10 DE DE69429435T patent/DE69429435T2/de not_active Expired - Lifetime
- 1994-08-10 BR BR9407293A patent/BR9407293A/pt not_active Application Discontinuation
- 1994-08-10 NZ NZ273292A patent/NZ273292A/en not_active IP Right Cessation
- 1994-08-10 CN CN94193106A patent/CN1086291C/zh not_active Expired - Lifetime
- 1994-08-10 AT AT94926828T patent/ATE210442T1/de active
- 1994-08-10 JP JP7506731A patent/JPH09501664A/ja active Pending
- 1994-08-10 CA CA002169718A patent/CA2169718C/en not_active Expired - Lifetime
- 1994-08-10 CZ CZ1996465A patent/CZ289040B6/cs not_active IP Right Cessation
- 1994-08-10 US US08/602,742 patent/US5721258A/en not_active Expired - Lifetime
- 1994-08-15 YU YU51294A patent/YU49215B/sh unknown
- 1994-08-16 ZA ZA946176A patent/ZA946176B/xx unknown
- 1994-08-16 IL IL11068194A patent/IL110681A/xx not_active IP Right Cessation
- 1994-08-16 HR HRP4327516.8A patent/HRP940464A2/hr not_active Application Discontinuation
- 1994-10-08 UA UA96030972A patent/UA43351C2/uk unknown
- 1994-10-25 EE EE9400160A patent/EE03204B1/xx unknown
-
1996
- 1996-02-14 BG BG100356A patent/BG62430B1/bg unknown
- 1996-02-15 NO NO960607A patent/NO309842B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960703591A (ko) | 신경변성 질병에서 플로피르틴의 일차적 및 이차적 신경보호 효과(The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases) | |
HUP9802862A2 (hu) | (1S,2S)-1-(4-hydroxi-fenil)-2-(4-hidroxi-4-fenil-1-piperidinil)-1-propanol-metánszulfonát-trihidrát, és ezt a vegyületet tartalmazó a központi idegrendszeri rendellenességek kezelésére alkalmas gyógyászati készítmények | |
GEP20033027B (en) | Use of Substituted Benzopyran Analogs for Treatment of Inflammation | |
PT1040830E (pt) | Medicamento para doencas neurodegenerativas | |
KR960700742A (ko) | 아토피성질환 치료약(atopic disease remedy) | |
HUP9904525A2 (hu) | S-(-)-N-Propargil-1-amino-indán tartalmú neurológiai rendellenességek kezelésére alkalmas gyógyszerkészítmények | |
MX9207495A (es) | Compuestos de tetrahidroisoquinolina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. | |
AU3632497A (en) | Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease | |
WO2001041768A3 (en) | Use of hymenialdisine or derivatives thereof in the manufacture of medicaments | |
BR9907953A (pt) | Inibidores de transporte de glicina | |
RU96105707A (ru) | Лекарственное средство для лечения дегенеративных заболеваний нервной системы | |
AR020762A1 (es) | El uso de carnitina y resveratrol para producir una composicion para la prevencion o el tratamiento terapeutico de los trastornos cerebrales provocados porel envejecimiento y el uso de drogas neurotoxicas | |
ECSP034518A (es) | Nuevos retinoides para el tratamiento de enfisema | |
BR0210650A (pt) | Tablete, e, uso do mesmo | |
ZA912652B (en) | Use of n-alkylated 1,4-dihydropyridinedicarboxylic acid esters as medicaments,new compounds and processes for their preparation | |
DE69725549D1 (de) | Isochinolderivate | |
AR066455A2 (es) | Uso de compuestos n-metil-n-[(1r)-1-fenil-2-(3r)-3-hidroxipirrolidin -1-il-=-etil]-2,2-difenilacetamida para producir un medicamento para el tratamiento de emfermedades intestinales no inflamatorias | |
BG108452A (en) | Tablet comprising cetirizine and pseudoephedrine | |
HUP0300863A2 (hu) | N-(3,5-diklór-2-metoxi-fenil)-4-metoxi-3-(1-piperazinil)-benzolszulfonamid, eljárás elżállítására és a vegyületet tartalmazó gyógyszerkészítmény | |
TNSN97143A1 (fr) | Derives de trans-piperazine-1-yl-spiro(cyclohexane-1, 1'- isobenzofuranne), procede pour leur preparation et compositions pharmaceutiques les contenant | |
YU21096A (sh) | Benzamidska jedinjenja, postupci dobijanja i farmaceutski preparati koji sadrže ova benzamidska jedinjenja | |
WO2004082699A3 (de) | Verwendung von weihrauch oder seinen hydrierungsprodukten zur prophylaxe und/oder behandlung von zerebraler ischämie und/oder schädel/hirntrauma | |
BRPI0413101A (pt) | compostos de sulfonamida derivado de benzoxazinona, sua preparação e uso como medicamentos | |
RU97104062A (ru) | Применение селегилина для лечения эпилептических заболеваний | |
ES2140544T3 (es) | Utilizacion de efaroxan y de sus derivados para la fabricacion de medicamentos destinados al tratamiento de las enfermedades neurodegenerativas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
N231 | Notification of change of applicant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130530 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20140530 Year of fee payment: 13 |